Stocks / Biotech
CRSPBiotech
CRISPR Therapeutics AG
$57.001d +9.2%5d +9.1%settled close · 2026-09-17
Mkt cap $4.5B (3/25)β 1.7452w $44–77Shares 96.0MInd. Biological Products, (No Diagnostic Substances)Nasdaq since 2016Emp. 393HQ Zugcrisprtx.com
The tape, with the calls on it
Who said what, and what CRSP did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
bullish
bearish
both sides
Who’s talkingIdea Scout · free
Who’s talking about CRSP
2 longlatest 2025-12-04
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2025-12-04 | Cathie WoodCEO & CIO, ARK Invest | Bullish | Money Maze Podcast | CRISPR Therapeutics is expanding from proven rare-disease cures (sickle cell, beta-thalassemia) into… |
| 2025-06-05 | Cathie WoodCEO & CIO, ARK Invest | Bullish | Chris Davis | CRISPR Therapeutics has commercialized the first gene-editing cure for sickle cell disease and beta… |
1 new mention of CRSP this week is in The Brief — who, which way, and what they said, in subscribers’ inboxes every morning. Free pages update a week later.
Get The Brief — $20/mo →
Earnings
Next report: 9 Nov 2026
Confirmed date · consensus EPS -1.05. Reactions below are the next settled session over the prior close.
The options tapeThe Brief · paid
Notable options days
Sessions in the last 120 where CRSP’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 10 of 120 sessions qualified.
The qualifying dates are the free record. Close, flow, call/LEAPS mix and the 20-session outcome — for every session below — are Brief subscriber content.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-09-17 | ||||||
| 2026-08-25 | ||||||
| 2026-08-20 | ||||||
| 2026-08-19 | ||||||
| 2026-06-04 | ||||||
| 2026-04-17 | ||||||
| 2026-04-16 | ||||||
| 2026-04-15 | ||||||
| 2026-04-14 | ||||||
| 2026-04-13 |
+20 sess. = raw price change over the following 20
sessions — not market-adjusted; the tape tells you where to look,
not what happens next.
Today’s tape on
CRSP is in this morning’s Brief.
Get The Brief — $20/mo →